Benzo[d]imidazole-based binimetinib (Mektovi, ARRY-162) (39 in Figure 5) is a MEK1/2 inhibitor approved in 2018 for the treatment of unresectable or metastatic melanoma with BRAF mutations, in association with encorafenib, a MAPK inhibitor. This evidence concerns the gene BRAF and metastatic melanoma.